These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10266242)

  • 1. Drug selection in a regulated society: the Norwegian experience.
    Bakke OM
    Hosp Formul; 1984 May; 19(5):411-2, 415, 418 passim. PubMed ID: 10266242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Editorial: Information committee of the drug industry].
    Naes K
    Tidsskr Nor Laegeforen; 1975 Oct; 95(30):1748-9. PubMed ID: 1188879
    [No Abstract]   [Full Text] [Related]  

  • 6. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of a drug and therapeutics committee in primary health care. Experiences from the 16/Furuset District, Oslo].
    Gorlén T; Juvkam E; Westly T
    Tidsskr Nor Laegeforen; 1991 Jun; 111(16):1995-6. PubMed ID: 1866738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Criteria for choice of preparations in a drug committee].
    Lunde PK
    Tidsskr Nor Laegeforen; 1975 Jan; 95(1):37-40. PubMed ID: 1111161
    [No Abstract]   [Full Text] [Related]  

  • 9. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Work of the committee on drug side effects].
    Naes K
    Tidsskr Nor Laegeforen; 1975 Aug; 95(22):1237-8. PubMed ID: 1162664
    [No Abstract]   [Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacists' and general practitioners' views on parallel import of drugs].
    Gundersen R; Torgauten O; Olsen H
    Tidsskr Nor Laegeforen; 1999 Apr; 119(11):1586-8. PubMed ID: 10385799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug committees in hospitals].
    Flatberg P
    Tidsskr Nor Laegeforen; 1975 Jan; 95(1):36-7. PubMed ID: 1111160
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of drug statistics in hospitals].
    Skobba TJ; Lunde PK
    Tidsskr Nor Laegeforen; 1975 Jan; 95(1):40-1. PubMed ID: 1111162
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experiences in approving drugs].
    Schnieders B
    Internist (Berl); 1980 Jun; 21(6):325-32. PubMed ID: 7005169
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug evaluation: new requirements and perspectives].
    Addis A; Rocchi F
    Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in the sale and use of flunitrazepam in Norway after 1999].
    Bramness JG; Skurtveit S; Furu K; Engeland A; Sakshaug S; Rønning M
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):589-90. PubMed ID: 16505866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When medicine becomes a disease.
    Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.